<DOC>
	<DOCNO>NCT02006459</DOCNO>
	<brief_summary>We want investigate mechanism extrapancreatic effect gastrointestinal-mediated glucose disposal . In order perform oral glucose tolerance test isoglycemic intravenous glucose infusion total pancreatectomised patient healthy control .</brief_summary>
	<brief_title>Involvement Extrapancreatic Factors Gastrointestinal-mediated Glucose Disposal</brief_title>
	<detailed_description>In current project wish identify possible contribution extrapancreatic effect gastrointestinal-mediated glucose disposal ( GIGD ) . GIGD reflect percentage individual 's glucose disposal follow oral glucose tolerance test ( OGTT ) cause oral route glucose administration . In healthy subject GIGD amount ~60 % . GIGD describes impact incretin effect ( insulinotropic substance release upon intestinal stimulation ) include factor affect glucose disposal differently oral vs. iv administration glucose ( include neural reflex , activation afferent nerve intestinal mucosa , difference glucagon secretion , hepatic glucose production first-pass hepatic uptake glucose , difference portal venous blood glucose concentration and/or present unknown factor . It likely incretin effect ( pancreatic effect ) constitute major contributor GIGD , far impossible discriminate pancreatic extrapancreatic mechanism underlie GIGD</detailed_description>
	<criteria>Pancreatectomized patient Caucasians 18 year age undergone total pancreatectomy Normal haemoglobin Informed consent Healthy Subjects Normal fast plasma glucose ( FPG ) normal HbA1C ( accord World Health Organization ( WHO ) criterion ) Normal haemoglobin Age 18 year Informed consent Pancreatectomized patient Inflammatory bowel disease Operation within last 3 month Ongoing chemotherapy chemotherapy within last 3 month Ostomy Nephropathy ( serum creatinine &gt; 150 µM and/or albuminuria ) Severe liver disease ( serum alanine aminotransferase ( ALAT ) and/or serum aspartate aminotransferase ( ASAT ) &gt; 3×normal value ) Pregnancy and/or breastfeed Age 80 year Any condition investigator feel would interfere trial participation Healthy Subjects Diabetes mellitus ( DM ) Prediabetes ( impaired glucose tolerance and/or impair FPG ) First degree relative DM Inflammatory bowel disease Intestinal resection and/or ostomy Nephropathy ( serum creatinine &gt; 150 µM and/or albuminuria Liver disease ( ALAT and/or serum ASAT &gt; 2×normal value ) Pregnancy and/or breastfeed Age 80 year Any condition investigator feel would interfere trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Gastrointestinal-mediated glucose disposal</keyword>
	<keyword>Total pancreatectomy</keyword>
	<keyword>Incretin hormone</keyword>
	<keyword>Glucagon</keyword>
</DOC>